Global Glaucoma Treatment Market Size To Grow USD 10.5 Billion by 2032 | CAGR of 5.0%
The Global Glaucoma Treatment Market Size was valued at USD 6.4 Billion in 2022 and the Worldwide Glaucoma Treatment Market…
24,828€
-0,69%
Echtzeit-Aktienkurs Pfizer Inc.
Bid:
Ask:
Nachrichten zur Pfizer Inc. Aktie
[Latest] Global Acne Treatment Market Size/Share Worth USD 18.77 Billion by 2032 at a 6.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…
Oncology Drug Discovery & Development Market Expected to Grow at a CAGR of 18.2% from 2023 to 2031 | Reveals InsightAce Study
Companies covered in this study are Novartis, AstraZeneca, Merck & Co., Inc, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, Gilead…
Pfizers stock price is at a three-year low. Is it time to buy?
This heavily sold-off pharma stock is a bargain, so is it time to buy?…
Europäisches Patentamt erklärt Moderna-Patent für nichtig
Frankfurt (Reuters) - Das Europäische Patentamt hat im Patentstreit zwischen den beiden Corona-Impfstoffherstellern BioNTech und Moderna ein mRNA-Patent des US-Biotechkonzerns…
Pfizer Is A Fantastic Buy And So Are These 9%-Yielding Blue Chips
…
Impfstoffentwickler: EU-Patentamt hat Moderna-Patent für nichtig erklärt
Ende August hatte die US-Biotech-Firma Moderna das Mainzer Unternehmen Biontech und dessen US-Partner Pfizer verklagt. Das Urteil fiel nun zugunsten…
Texas AG sues Pfizer over quality-control lapses in kids ADHD drug By Reuters
Texas AG sues Pfizer over quality-control lapses in kids ADHD drug…
Texas AG sues Pfizer for alleged Medicaid fraud over ADHD meds
…
Pfizer Is Working on Oral Alternative to Ozempic
Pfizer CEO Albert Bourla says the drug maker is hoping to develop an oral anti-obesity drug that can rival Ozempic.…
Basilea Pharmaceutica AG: Weiterhin gute Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen dritte Meilensteinzahlung von Pfizer in diesem Jahr für diese Region aus
Allschwil, 20. November 2023 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel,…
GNW-Adhoc: Weiterhin gute Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen dritte Meilensteinzahlung von Pfizer in diesem Jahr für diese Region aus
^Allschwil, 20. November 2023 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel,…
GNW-Adhoc: Weiterhin gute Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen dritte Meilensteinzahlung von Pfizer in diesem Jahr fü...
^Allschwil, 20. November 2023Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutischesUnternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zuhelfen,…
GlobeNewswire: Weiterhin gute Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen dritte Meilensteinzahlung von Pfizer in diesem Jahr für diese Region aus
Weiterhin gute Cresemba® (Isavuconazol)-Umsätze in der Region Asien-Pazifik und China lösen dritte Meilensteinzahlung von Pfizer in diesem Jahr für diese…
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this year
Allschwil, Switzerland, November 20, 2023…
Pfizer Stock: Cheap But Will Remain Cheap, For Now
…
Why the Cheapest Stock in the S&P 500 Is No Bargain
Viatris is the old generic drug company Mylan, acquired by Pfizer and merged with its Upjohn division. The stock has…
AbbVie and Pfizer Have 1 Thing in Common: Their Biggest Products Are on the Decline. Time to Sell?
Both companies share prices have slipped recently.…
AbbVie and Pfizer Have 1 Thing in Common: Their Biggest Products Are on the Decline. Time to Sell? @themotleyfool #stocks $ABBV $PFE
Both companies share prices have slipped recently.…
Pfizers (PFE) New Products May Drive Long-Term Sales Growth
Though Pfizers (PFE) revenues from COVID products are declining sharply, the launch of some key non-COVID products in 2023 is…
Eli Lillys Olumiant and Pfizers Litfulo Strengthen Alopecia Areata Arsenal, Yet Resounding Opportunity for JAK Expansion and New Assets in Development Remain
Despite little prescriber differentiation between the JAKs, including satisfaction and manufacturer perceptions, Olumiant is projected to maintain a significant market…
Pfizer to halve UK workforce at Discovery Park
Pfizer Inc (NYSE:PFE) has said it will lay off more than half of its employees at a UK-based scientific research centre…
Pfizer: Victim Of Vaccine Side Effects
…
Pfizer to shed 500 jobs at England site as cost-cutting ramps up
…
Pfizer to cut 500 jobs at Kent site
Pfizer is cutting 500 jobs at its Sandwich, Kent site in the U.K. as part of a cost-cutting effort, Sky…
Pfizer to cut 500 jobs at Kent site - Sky News By Reuters
Pfizer to cut 500 jobs at Kent site - Sky News…
Better Growth Stock: Pfizer vs. Novo Nordisk
One is growing now, and the other will grow soon.…
Top Analyst Reports for Meta Platforms, Walmart & Pfizer
Todays Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc. (META), Walmart Inc. (WMT) and…
Pfizer Stock Hits 3-Year Low—Down 50% From 2021 Peak
Excluding a brief early 2020 plunge, Pfizer shares are now trading at their lowest level since 2016.…
US Gastroenterologist Projections Suggest Significant Shift in Ulcerative Colitis Landscape Afoot, with Launches of Eli Lillys Omvoh, Pfizers Velsipity, Takedas Subcutaneous Entyvio, and Celltrions Zymfentra
Prior to launch, prescribers estimate that TNF inhibitors are likely to bear the greatest brunt of increased adoption of the…
Opening Bell: US-Investoren vor Inflationsdaten an der Seitenlinie; Pfizer, AMD, Palo Alto Networks, Dell, Waste Management im Fokus
Am Freitag noch im Rally-Modus, zum Wochenauftakt an der Seitenlinie: Die US-Investoren üben sich am Montag in Zurückhaltung. In der…
Pfizer wants in on the weight loss drug market – and upcoming data will be crucial for its success
Analysts said upcoming data on Pfizers obesity pill, danuglipron, will be crucial to how competitive the company can be against…
Eilt: Biotech Hot Stock unmittelbar vor globalem Lizenzdeal. Neuer 384% Biotech Aktientip nach 10.996% mit Pfizer ($PFE)
Calgary (www.aktiencheck.de, Anzeige)
Einschätzung
Strong OutperformerKurszieleKursziel 12M: 9 USD
Kurschance: 223%
Kursziel 24M: 13,50 USD
Kurschance: 384%StammdatenISIN: CA98420Q3061
WKN: A3EUNZ
Ticker: ANUA
TSXV: XRTX.V
NASDAQ: XRTXKursdatenKurs: 2,79 USD
52W Hoch:…
Pfizer Inc. (PFE) Presents at Truist Securities BioPharma Symposium (Transcript)
…
ACHV: Ancillary Studies Complete
By John Vandermosten, CFA
NASDAQ:ACHV
READ THE FULL ACHV RESEARCH REPORT
Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported third quarter 2023 results in a…
Pfizer may file substantial compliance with FTC on Seagen in 3-4 weeks - CNBC
…
Zacks Earnings Trends Highlights: Pfizer, Eli Lilly, General Motors and Tesla
Pfizer, Eli Lilly, General Motors and Tesla have been highlighted in this Earnings Trends article.…
: Syphilis cases among newborns are skyrocketing, CDC says
Pfizer works to speed production of key penicillin as officials see "unacceptable American crisis," underscoring need for rapid testing and…
Pfizer to Cut $3.5B in Costs, Close NJ Plant
…
PLX: More Regulatory Approvals
By John Vandermosten, CFA
NYSE:PLX
READ THE FULL PLX RESEARCH REPORT
Third Quarter 2023 Financial and Operational Review
Protalix Biotherapeutics, Inc. (NYSE:PLX) announced 3Q:23…
BioNTech Earnings Beat. Pfizer’s Vaccine Partner Battles Covid Downturn.
…
ROUNDUP: Biontech erwartet weniger Umsatz mit Corona-Impfstoff
MAINZ (dpa-AFX) - Das Biotechnologieunternehmen Biontech hat wie andere Hersteller mit dem schrumpfenden Absatz von Covid-19-Impfstoffen zu kämpfen. Die…
: BioNTech’s stock rallies after it posts surprise Q3 profit and revenue that tops estimates
BioNTech SE’s stock BNTX rallied premarket after the company posted a surprise profit for the third quarter and revenue that…
Pfizer: Hohe Kosten, schwächelnde Pipeline und Rückgang der COVID-19-Umsätze - Aktienanalyse
Wien (www.aktiencheck.de) - Pfizer-Aktienanalyse von der Raiffeisen Bank International AG:
Raphael Schicho, Analyst der Raiffeisen Bank International AG (RBI), rät in…
BioNTech und Bayer unter Druck - Defence Therapeutics dagegen mit guten Resultaten. Wo lohnt der Einstieg?
Derzeit gibt es in der Pharma- und Biotechbranche große Verlierer unter den Unternehmen, welche die größten Profiteure der Corona Krise…
Sosei Heptares’ Partner, Pfizer, Progresses Its GLP-1 Receptor Agonist PF-06954522 into a Phase 1 Trial
Tokyo, Japan and Cambridge, UK, 06 November 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) has…
Did Barron’s nail the peak in yields?
The old adage is that magazine covers are a jinx. That’s particularly true with The Economist but Barron’s has had…
Pfizer: Neues Kursziel
London (www.aktiencheck.de) - Rating-Update:
Die Analysten von Barclays stufen die Aktie von Pfizer Inc. (ISIN: US7170811035, WKN: 852009, Ticker-Symbol: PFE, NYSE-Symbol:…
Dividend Roundup: ConocoPhillips, IBM, Honeywell, Pfizer, and more
…
Theres a Silver Lining in Pfizers Dark Cloud. Should You Buy the Stock?
Its important to look at Pfizer through a long-term lens.…